Development of Resistance to Molecularly Targeted Therapy in BRAF V600 Emulated Metastatic Colorectal Cancer (PARTACER-Suisse)

In this study, patients with metastatic colorectal cancer with a proven BRAF V600E mutation receive targeted therapy with the drugs cetuximab and encorafenib.

Aim of the study

The aim of this study is to investigate the biological mechanisms that lead to the development of resistance to targeted therapies in patients with advanced BRAF-mutated colorectal cancer. Through the comparative analysis of tumor, blood and stool samples before the start of therapy and at disease progression, as well as through the production of organoids, we hope to better understand why treatment with cetuximab and encorafenib loses efficacy over time. These findings should contribute to the development of more effective and individualized therapeutic approaches in the future.

Who can take part?

Patients who have metastatic colorectal cancer with evidence of the BRAF V600E mutation.